戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 HLMCs were present, but this was reversed by fluticasone.
2 any effect on suppression of inflammation by fluticasone.
3 cantly lower doses and with lower costs than fluticasone.
4  95% CI, 0.73-0.93) than patients started on fluticasone.
5 nt prescribed HFA-beclomethasone rather than fluticasone.
6 n with the corticosteroids dexamethasone and fluticasone.
7 e to severe COPD can be reduced by high-dose fluticasone.
8 100 microg twice daily) to receive continued fluticasone (100 microg twice daily) (169 patients), mon
9 h asthma that was well controlled by inhaled fluticasone (100 microg twice daily) to receive continue
10 t (5 or 10 mg each night) (166 patients), or fluticasone (100 microg) plus salmeterol (50 microg) eac
11 y TNFalpha alone was completely abrogated by fluticasone (100 nM), dexamethasone (1 microM), or budes
12 pregnancy (n = 1231; 79.9% budesonide, 17.6% fluticasone, 5.4% beclomethasone, and 0.9% other or unsp
13 rol (50 mug) plus the inhaled glucocorticoid fluticasone (500 mug) twice daily.
14 onsiveness to methacholine, received inhaled fluticasone (880 microg daily) for 12 weeks.
15 t this hypothesis, we studied the effects of fluticasone, AC, or both on AMos of C57BL/6 mice in vitr
16                           Patients receiving fluticasone achieved a significantly higher rate of clin
17 e hydrofluoroalkane (HFA)-beclomethasone and fluticasone administered through a pressurized metered-d
18 1), salmeterol (73 mL, 46-101, p<0.0001), or fluticasone alone (95 mL, 67-122, p<0.0001).
19 ve fluticasone propionate plus salmeterol or fluticasone alone for 26 weeks.
20 eceive either fluticasone with salmeterol or fluticasone alone for 26 weeks.
21 ard ratio with fluticasone-salmeterol versus fluticasone alone was 1.28 (95% confidence interval [CI]
22  Noninferiority of fluticasone-salmeterol to fluticasone alone was defined as an upper boundary of th
23 ated event that was similar to the risk with fluticasone alone.
24 a-related events than did those who received fluticasone alone.
25 e fluticasone-salmeterol group and 21 in the fluticasone-alone group had a serious asthma-related eve
26 sone-salmeterol group and 309 (10.0%) in the fluticasone-alone group had a severe asthma exacerbation
27                                              Fluticasone, an inhaled steroid commonly used to treat a
28 with fluticasone/salmeterol (64% vs 23% 2.5x fluticasone and 13% fluticasone/montelukast in the Best
29                                     In vitro fluticasone and budesonide reduced MR1 surface expressio
30 reated with topical corticosteroids, such as fluticasone and budesonide, or dietary strategies, such
31 nd CCL5 by TNF-alpha was insensitive to both fluticasone and dexamethasone in ASM cells from severe a
32 ing their first ICS as HFA-beclomethasone or fluticasone and matched on baseline demographic characte
33  interferon (IFN) beta was administered with fluticasone and rhinovirus 1B in both groups of mice.
34 asal recombinant IFN beta (10(4) units) with fluticasone and rhinovirus 1B led to upregulation of int
35 P-10 compared with control mice treated with fluticasone and rhinovirus alone and improved viral clea
36          All participants received high-dose fluticasone and salmeterol and continued other pre-study
37  study evaluates the contribution of inhaled fluticasone and salmeterol, alone or combined, to the re
38 d additively and synergistically enhanced by fluticasone and salmeterol, respectively.
39 ha-treated HASM cells, which was enhanced by fluticasone and salmeterol.
40 nd additively enhanced by the glucocorticoid fluticasone and the beta(2)-agonist salmeterol, whereas
41 ilanterol); a control arm (not given inhaled fluticasone); and pre-randomisation measurements of bloo
42  and 336 patients randomized to montelukast, fluticasone, and placebo, respectively.
43                                  15d-PGJ(2), fluticasone, and salmeterol all inhibited TNFalpha-induc
44 from the run-in period of open-label inhaled fluticasone, and the treatment periods for subjects rand
45          Combined activity of salmeterol and fluticasone at equimolar concentrations had no effect on
46 ntrolled with the use of twice-daily inhaled fluticasone can be switched to once-daily fluticasone pl
47 fluticasone DPI - 445; budesonide DPI - 268; fluticasone-CFC MDI - 111.
48 e dry powder inhaler [DPI], fluticasone DPI, fluticasone-CFC metered dose inhaler [MDI], flunisolide-
49                                 Halcinonide, fluticasone, clobetasol, and fluocinonide provide an unp
50 tified four FDA-approved drugs, halcinonide, fluticasone, clobetasol, and fluocinonide, as Smo agonis
51 a2-agonist/inhaled corticosteroid salmeterol/fluticasone combination 50/500 mug in patients with one
52 nced by suppressed BAL neutrophil numbers in fluticasone compared with control mice (0.021 x 10(5) [0
53  salmeterol in a fixed-dose combination with fluticasone did not have a significantly higher risk of
54 sponse returned to normal 9 months after the fluticasone dose was reduced to 500 micrograms/day.
55 lomethasone doses were lower (P < .001) than fluticasone doses (median, 320 mug/d [interquartile rang
56 inolone-CFC - 787; beclomethasone-CFC - 548; fluticasone DPI - 445; budesonide DPI - 268; fluticasone
57 iamcinolone-CFC), only the placebo group and fluticasone DPI did not demonstrate a significant dose-r
58  [CFC], budesonide dry powder inhaler [DPI], fluticasone DPI, fluticasone-CFC metered dose inhaler [M
59 ects randomized to (1) continued twice daily fluticasone (F), (2) once daily fluticasone plus salmete
60                            More importantly, fluticasone failed to induce GRE-dependent gene transcri
61 ium was significantly superior to salmeterol/fluticasone for the prevention of exacerbations (all sev
62 95% CI 0.75-1.14]) with similar findings for fluticasone furoate (0.90 [0.72-1.11]) and vilanterol (0
63 , vilanterol (25 mug), or the combination of fluticasone furoate (100 mug) and vilanterol (25 mug).
64 locks to receive once daily inhaled placebo, fluticasone furoate (100 mug), vilanterol (25 mug), or t
65 ear [95% CI 1-15]) with similar findings for fluticasone furoate (difference 8 mL per year [95% CI 1-
66  the once-daily inhaled corticosteroid (ICS) fluticasone furoate (FF) and long-acting beta(2) -agonis
67                                              Fluticasone furoate (FF) is a novel, once-daily ICS asth
68   Genotyping and imputation was performed in fluticasone furoate (FF) or fluticasone propionate-treat
69 ontrolled trial, once-daily inhaled placebo, fluticasone furoate (FF; 100 mug), vilanterol (VI; 25 mu
70 ere pretreated with either cetirizine 10 mg, fluticasone furoate 27.5 mug, or placebo to alleviate th
71 randomly assigned to initiate treatment with fluticasone furoate and vilanterol (n=2114) or usual car
72 V1) and the increased risk of pneumonia with fluticasone furoate and vilanterol compared with vilante
73 ightened cardiovascular risk, treatment with fluticasone furoate and vilanterol did not affect mortal
74 hose on usual care (977 [71%] of 1373 in the fluticasone furoate and vilanterol group vs 784 [56%] of
75 f a once-daily treatment regimen of combined fluticasone furoate and vilanterol improved asthma contr
76 Across all doses of inhaled corticosteroids, fluticasone furoate and vilanterol reduced exacerbations
77 er for patients who initiated treatment with fluticasone furoate and vilanterol than for those on usu
78 fractures were reported more frequently with fluticasone furoate and vilanterol than with vilanterol
79 , a once-daily treatment regimen of combined fluticasone furoate and vilanterol was associated with a
80                         We hypothesised that fluticasone furoate and vilanterol would prevent more ex
81 patients (605 assigned to usual care, 602 to fluticasone furoate and vilanterol) had a baseline ACT s
82 ms (fluticasone propionate and salmeterol or fluticasone furoate and vilanterol); a control arm (not
83 nts from baseline in patients initiated with fluticasone furoate and vilanterol, compared with 2.8 po
84             Reductions in exacerbations with fluticasone furoate and vilanterol, compared with vilant
85  COPD to a once-daily inhaled combination of fluticasone furoate at a dose of 100 mug and vilanterol
86 tion; 4111 in the placebo group, 4135 in the fluticasone furoate group, 4118 in the vilanterol group,
87 18% in the combination group, and 17% in the fluticasone furoate group, and 17% in the vilanterol gro
88 roup, 6% in the combination group, 5% in the fluticasone furoate group, and 4% in the vilanterol grou
89  vilanterol plus 50 mug, 100 mug, or 200 mug fluticasone furoate in patients with moderate-to-severe
90 ng-term effect of the inhaled corticosteroid fluticasone furoate on exacerbation frequency.
91 ined with either 50 mug, 100 mug, or 200 mug fluticasone furoate once daily.
92                                  Addition of fluticasone furoate to vilanterol was associated with a
93 led combination of either 100 mug or 200 mug fluticasone furoate with 25 mug vilanterol or optimised
94                                              Fluticasone furoate, alone or in combination with vilant
95  a combined treatment of the corticosteroid, fluticasone furoate, and the long-acting beta agonist, v
96 ative reduction; p=0.137) or the components (fluticasone furoate, HR 0.91 [0.77-1.08]; p=0.284; vilan
97  mug and vilanterol at a dose of 25 mug (the fluticasone furoate-vilanterol group) or to usual care (
98 s serious adverse events of pneumonia in the fluticasone furoate-vilanterol group.
99 (95% confidence interval, 1.1 to 15.2), with fluticasone furoate-vilanterol therapy than with usual c
100 al pro-apoptotic effect of dexamethasone and fluticasone furoate.
101 aring 24 weeks of once-daily triple therapy (fluticasone furoate/umeclidinium/vilanterol 100 mug/62.5
102 led corticosteroid/long-acting beta2-agonist fluticasone furoate/vilanterol 100/25 mug or placebo (7-
103 bation rate was noted between the 200/25 mug fluticasone furoate/vilanterol group and the vilanterol
104 ight deaths from pneumonia were noted in the fluticasone furoate/vilanterol groups compared with none
105 e and severe exacerbations were noted in all fluticasone furoate/vilanterol groups than in the vilant
106 e and severe exacerbations were noted in all fluticasone furoate/vilanterol groups than in the vilant
107                                              Fluticasone furoate/vilanterol safety profile was simila
108 P < 0.001) reduction in residual volume with fluticasone furoate/vilanterol versus placebo.
109 -glycopyrronium group than in the salmeterol-fluticasone group (0.98 vs. 1.19; rate ratio, 0.83; 95%
110 -glycopyrronium group than in the salmeterol-fluticasone group (3.59 vs. 4.03; rate ratio, 0.89; 95%
111 e first exacerbation than did the salmeterol-fluticasone group (71 days [95% CI, 60 to 82] vs. 51 day
112 -glycopyrronium group than in the salmeterol-fluticasone group (hazard ratio, 0.78; 95% CI, 0.70 to 0
113 copyrronium group and 4.8% in the salmeterol-fluticasone group (P=0.02).
114                        Fewer patients in the fluticasone group withdrew from the study due to lung-re
115 e combination-therapy group and 18.3% in the fluticasone group) than in the placebo group (12.3%, P<0
116 opyrronium group, and 1682 to the salmeterol-fluticasone group.
117 5% in the salmeterol group, and 16.0% in the fluticasone group.
118                                              Fluticasone group: n=84, median age 14.6 yr, mean (SD) F
119                   The efficacy and safety of fluticasone has been established at recommended doses of
120                        Patients treated with fluticasone improved significantly more rapidly (median
121 fter therapy with the inhaled corticosteroid fluticasone in independent cohorts.
122 bo-controlled trial of pre-emptive high-dose fluticasone in preschoolers with URTI-induced asthma.
123 bo-controlled trial of pre-emptive high-dose fluticasone in preschoolers with virus-induced asthma.
124 pyrronium was more effective than salmeterol-fluticasone in preventing COPD exacerbations in patients
125 feriority but also superiority to salmeterol-fluticasone in reducing the annual rate of all COPD exac
126 to continued triple therapy or withdrawal of fluticasone in three steps over a 12-week period.
127                                 By contrast, fluticasone increased MUC5AC proteins (158.2 arbitrary u
128        KCa3.1 channel blockade also restored fluticasone-induced GC receptor-alpha phosphorylation at
129                                              Fluticasone-induced GRalpha nuclear translocation, phosp
130 om hospital patients were given a salmeterol/fluticasone inhaler with an INCA device attached.
131              Despite increasing viral loads, fluticasone inhibited rhinovirus-induced airway inflamma
132 nificantly lower for HFA-beclomethasone than fluticasone (mean, $1869 [95% CI, $1727-$2032] vs $2259
133                   Fluticasone/salmeterol and fluticasone monotherapy decreased peripheral airway smoo
134                   Fluticasone/salmeterol and fluticasone monotherapy equally reverse peripheral airwa
135 meterol (64% vs 23% 2.5x fluticasone and 13% fluticasone/montelukast in the Best ADd-on Therapy Givin
136 iver homogenate reference sample, except for fluticasone, nicardipine, and sorafenib which suffer fro
137 indacaterol-glycopyrronium versus salmeterol-fluticasone on the rate of COPD exacerbations was indepe
138 the fluticasone-salmeterol group than in the fluticasone-only group (hazard ratio, 0.79; 95% CI, 0.70
139 pared with 597 of 5845 patients (10%) in the fluticasone-only group (P<0.001).
140  no asthma-related deaths; 2 patients in the fluticasone-only group underwent asthma-related intubati
141 ol group and 38 events in 33 patients in the fluticasone-only group.
142 e asthma exacerbations than did those in the fluticasone-only group.
143 ere defined as daily therapy with 500 mug of fluticasone or greater with or without a long-acting bet
144  received fluticasone; they then took either fluticasone or placebo for 6 mo.
145 0% of patients assigned to receive continued fluticasone or switched to treatment with fluticasone pl
146  45% (montelukast, P < .05 vs placebo), 49% (fluticasone, P < .001 vs placebo), and 39% (placebo); th
147 one twice daily (ICS step-up), 100 microg of fluticasone plus 50 microg of a long-acting beta-agonist
148                            Mice treated with fluticasone plus AC before infection with viable pneumoc
149 ment to the lungs at 48 h postinfection, and fluticasone plus AC less markedly reduced in vitro media
150                                              Fluticasone plus AC significantly reduced in vitro AMo k
151                                              Fluticasone plus AC significantly reduced TLR4-stimulate
152  twice daily fluticasone (F), (2) once daily fluticasone plus salmeterol (F + S), or (3) once daily o
153 se budesonide plus formoterol, or fixed-dose fluticasone plus salmeterol for 6 months.
154 se budesonide plus formoterol and fixed-dose fluticasone plus salmeterol for 7 months.
155 ed fluticasone or switched to treatment with fluticasone plus salmeterol had treatment failure, as co
156 ed fluticasone can be switched to once-daily fluticasone plus salmeterol without increased rates of t
157 thasone, methylprednisolone, budesonide, and fluticasone, potentiated TGF-beta signaling by the Acvrl
158                                              Fluticasone produced a wide spectrum of changes in the b
159    C57BL/6 mice were intranasally dosed with fluticasone propionate (1 mg/kg) or vehicle (dimethyl su
160 ma and treated them for 30 days with inhaled fluticasone propionate (1,760 microg/day) followed by a
161 ng patients receiving medications containing fluticasone propionate (19.6% in the combination-therapy
162 twice daily), and the inhaled glucocorticoid fluticasone propionate (500 mug twice daily) during a 6-
163 percentage difference, -15%; P = .0115), and fluticasone propionate (absolute difference, -1.64; perc
164 ve asthma predictive index to treatment with fluticasone propionate (at a dose of 88 mug twice daily)
165 fits of combining an inhaled corticosteroid, fluticasone propionate (F), with an inhaled long-acting
166  FF 50 mcg dosed in the evening, twice-daily fluticasone propionate (FP) 100 mcg or placebo.
167 lind, crossover study evaluating twice daily fluticasone propionate (FP) 100 mug, FP 500 mug and plac
168  crossover study and inhaled single doses of fluticasone propionate (FP) 100 mug, FP 500 mug, salmete
169 ment with salmeterol 50 microg combined with fluticasone propionate (FP) 250 microg, salmeterol 50 mi
170 , mean age 64 yr, were randomized to receive fluticasone propionate (FP) 500 microg twice daily (376
171 e efficacy and safety of high-dose swallowed fluticasone propionate (FP) and dose reduction in patien
172                  We evaluated the effects of fluticasone propionate (FP) and of salmeterol (SM), on t
173 ce were studied to determine whether inhaled fluticasone propionate (FP) could attenuate airway infla
174  we determined the effects of salmeterol and fluticasone propionate (FP) in seven steroid-naive patie
175 aimed to determine the efficacy of swallowed fluticasone propionate (FP) in the treatment of eosinoph
176 ); low (L), medium (M) and high (H) doses of fluticasone propionate (FP) L: 330 microg, M: 770 microg
177 ddition, the effects of IL-4, IFN-gamma, and fluticasone propionate (FP) on nasal epithelial cells we
178 antiinflammatory agents montelukast (ML) and fluticasone propionate (FP) on Qaw in 12 patients with m
179 the efficacy of MP-AzeFlu (Dymista((R)) ) vs fluticasone propionate (FP), (both 1 spray/nostril bid),
180 hages, matured in the presence or absence of fluticasone propionate (FP), and their ability to initia
181 ect of the highly lipophilic corticosteroid, fluticasone propionate (FP), in causing (1) inhibition o
182 ent study was to determine if an inhaled GS, fluticasone propionate (FP), similarly leads to vasocons
183  H3N2 and either or not treated with inhaled fluticasone propionate (FP), systemic corticosteroids (P
184 estigated the effects of importin-7 siRNA on fluticasone propionate (FP)-induced GR nuclear localizat
185 age I to II) before and after treatment with fluticasone propionate (FP)/salmeterol (SM) (50/500, 4 w
186 and assessed the effects of a 2-wk course of fluticasone propionate (FP; 440 microg daily) on these p
187     Two puffs (total dose, 200 microgram) of fluticasone propionate (n = 47) or placebo nasal spray (
188 propionate treatment regimens than with oral fluticasone propionate (with the exception of PEF rates
189 (with the exception of PEF rates for inhaled fluticasone propionate 100 micrograms) or placebo treatm
190 allergy were treated with run-in medication (fluticasone propionate 100 mug bid) during 2 weeks befor
191 d, double-blind, controlled study of inhaled fluticasone propionate 100 mug twice daily in young chil
192 re not under control by 3 months, open-label fluticasone propionate 100 mug twice daily was added to
193 wder 100 or 500 micrograms twice daily, oral fluticasone propionate 20 mg once daily, or placebo duri
194 lind study to placebo (n = 73) or salmeterol/fluticasone propionate 50/500 microg (n = 67) twice dail
195 29-02 (a novel formulation of azelastine and fluticasone propionate [FP]) in patients with moderate-t
196   The mortality rate for salmeterol alone or fluticasone propionate alone did not differ significantl
197  inhaler, with placebo, salmeterol alone, or fluticasone propionate alone for a period of 3 years.
198 ve with a combination product (100 microg of fluticasone propionate and 50 microg of salmeterol [FSC]
199 gate the effects of common asthma treatments fluticasone propionate and beta(2) agonists salmeterol a
200 n the 12 h after dosing, we monitored plasma fluticasone propionate and cortisol concentrations by ma
201  (inflammation and bronchoconstriction) with fluticasone propionate and salmeterol in a combination p
202  COPD that had: inhaled corticosteroid arms (fluticasone propionate and salmeterol or fluticasone fur
203 est that the therapeutic benefits of inhaled fluticasone propionate are mediated through topical effe
204  whether the therapeutic benefits of inhaled fluticasone propionate are mediated through topical or s
205                           When high doses of fluticasone propionate are used, growth may be retarded
206                         Systemic exposure to fluticasone propionate as assessed by trough plasma conc
207 aring salmeterol at a dose of 50 microg plus fluticasone propionate at a dose of 500 microg twice dai
208 tiotropium, 100 mug salmeterol, and 1000 mug fluticasone propionate daily for 6 weeks and were then r
209 0.3 +/- 15.2 years; ACT score, 14.6 +/- 3.8; fluticasone propionate dose, 718 +/- 470 mug).
210                     The early use of inhaled fluticasone propionate for wheezing in preschool childre
211                   Patients receiving inhaled fluticasone propionate had a significantly greater proba
212            The combination of salmeterol and fluticasone propionate has a broad spectrum of antiinfla
213      We investigated the pharmacokinetics of fluticasone propionate in patients with asthma receiving
214                    Some studies of high-dose fluticasone propionate in patients with no or mild asthm
215                     Systemic availability of fluticasone propionate is substantially less in patients
216 BI 671800 (50, 200, and 400 mg twice daily), fluticasone propionate nasal spray (200 mug once daily),
217  this study was to assess effects of inhaled fluticasone propionate on rhinovirus infection in vivo,
218 core >/=1.5) after uptitration to 1000 mug/d fluticasone propionate or greater were randomized to 3 o
219 r time compared with patients receiving oral fluticasone propionate or placebo (p = 0.001).
220 wer in the asthma group than in controls for fluticasone propionate plasma area under curve (1082 [95
221 ukast (our primary hypothesis) or once-daily fluticasone propionate plus salmeterol (our secondary hy
222 xacerbations in the previous year to receive fluticasone propionate plus salmeterol or fluticasone al
223 nd, run-in period were randomized to inhaled fluticasone propionate powder 100 or 500 micrograms twic
224            The potent topical glucocorticoid fluticasone propionate significantly suppressed dsRNA-de
225 ve analyses (AUC12) was higher with the oral fluticasone propionate than with the two inhaled flutica
226 tic children after introduction of high-dose fluticasone propionate treatment (dry powder).
227 icasone propionate than with the two inhaled fluticasone propionate treatment groups.
228 point were significantly higher with inhaled fluticasone propionate treatment regimens than with oral
229 tes, both 10 mg/d montelukast and 250 mug of fluticasone propionate twice daily significantly increas
230 evaluates 10 mg/d montelukast and 250 mug of fluticasone propionate twice daily, each compared with p
231                                              Fluticasone propionate was introduced in 1993 in the UK
232 rdation noted after treatment with high-dose fluticasone propionate were found to have adrenal suppre
233 over the benchmark inhaled corticosteroid 3 (fluticasone propionate) and prolonged the inhibition of
234 ly (fluticasone propionate), INCS on demand (fluticasone propionate) or oral antihistamine on demand
235 nolone acetonide, clobetasol propionate, and fluticasone propionate) predominantly accounted for GR a
236 ta2-agonist (salmeterol) and corticosteroid (fluticasone propionate) will reduce inflammation.
237         Patients received either INCS daily (fluticasone propionate), INCS on demand (fluticasone pro
238 oth TH1 and TH2 cytokines, was additive with fluticasone propionate, and inhibited cytokine release f
239  the safety of the LABA salmeterol, added to fluticasone propionate, in a fixed-dose combination in c
240  the results after adjustment for open-label fluticasone propionate, nor between the two groups in th
241  and primary cultures], roflumilast enhanced fluticasone propionate-induced GRE-dependent transcripti
242 was performed in fluticasone furoate (FF) or fluticasone propionate-treated patients with asthma from
243  combination with an inhaled glucocorticoid, fluticasone propionate.
244 daily for 7 days inhaled (via spacer device) fluticasone propionate.
245  group than in controls 4-12 h after inhaled fluticasone propionate.
246                    Inhaler monitors recorded fluticasone propionate/salmeterol adherence (covertly fo
247                         We found that the GC fluticasone rapidly and dose-dependently increased AC up
248                                              Fluticasone rapidly suppressed AMo expression of SIRPalp
249 superior or similar benefits over salmeterol/fluticasone regardless of blood eosinophil levels in pat
250 atics and PP5 knockdown using siRNA restored fluticasone repressive action on chemokine production an
251 l blockade led to a significant reduction of fluticasone-resistant CX3CL1, CCL5, and CCL11 gene and p
252  relapse in 14 randomized controlled trials (fluticasone: risk ratio, 1.31; 95% CI, 1.02-1.68; tacrol
253 LAME (Effect of Indacaterol Glycopyronium vs Fluticasone Salmeterol on COPD Exacerbations) study, whi
254 ic horses (6 horses/group) were treated with fluticasone, salmeterol, fluticasone/salmeterol, or with
255 to 2.27), which showed the noninferiority of fluticasone-salmeterol (P=0.006).
256  Among the 6208 patients, 27 patients in the fluticasone-salmeterol group and 21 in the fluticasone-a
257        A total of 265 patients (8.5%) in the fluticasone-salmeterol group and 309 (10.0%) in the flut
258 events, with 36 events in 34 patients in the fluticasone-salmeterol group and 38 events in 33 patient
259 ere asthma exacerbation was 21% lower in the fluticasone-salmeterol group than in the fluticasone-onl
260 io for a serious asthma-related event in the fluticasone-salmeterol group was 1.03 (95% confidence in
261 ccurring in 480 of 5834 patients (8%) in the fluticasone-salmeterol group, as compared with 597 of 58
262                           Patients receiving fluticasone-salmeterol had fewer severe asthma exacerbat
263                            Noninferiority of fluticasone-salmeterol to fluticasone alone was defined
264 ere hospitalizations); the hazard ratio with fluticasone-salmeterol versus fluticasone alone was 1.28
265 lung function cluster had best response with fluticasone/salmeterol (64% vs 23% 2.5x fluticasone and
266 e advertised during the period examined: (1) fluticasone/salmeterol (Advair), (2) mometasone furoate
267 ve effects in patients with asthma receiving fluticasone/salmeterol (FP/SM) combination and FP alone.
268                                    She is on fluticasone/salmeterol 500/50 mug one inhalation twice d
269                                              Fluticasone/salmeterol and fluticasone monotherapy decre
270                                              Fluticasone/salmeterol and fluticasone monotherapy equal
271         In conclusion, this study shows that fluticasone/salmeterol combination decreases extracellul
272                                         Only fluticasone/salmeterol decreased bronchoalveolar neutrop
273                          In central airways, fluticasone/salmeterol reversed extracellular matrix rem
274 ) were treated with fluticasone, salmeterol, fluticasone/salmeterol, or with antigen avoidance for 12
275 l subgroups, and at no cutoff was salmeterol/fluticasone superior to indacaterol/glycopyrronium.
276  was higher in patients receiving salmeterol/fluticasone than indacaterol/glycopyrronium in both the
277 NCS on-demand group used on average 61% less fluticasone than patients in the INCS daily group during
278                        In children receiving fluticasone, the ADYC score was significantly lower vers
279 he 2-mo run-in period, all patients received fluticasone; they then took either fluticasone or placeb
280                              The addition of fluticasone to xylometazoline and antimicrobial therapy
281  type I and III IFNs in the airways (for the fluticasone-treated group compared with controls: mean I
282 d IL-1beta-induced IL-6 production; however, fluticasone treatment caused a reduction of IL-6 protein
283 urfactant protein D inhibited AC uptake, and fluticasone treatment rapidly reversed this inhibition.
284                      At 24 h post infection, fluticasone treatment suppressed rhinovirus induction of
285                    Our findings suggest that fluticasone treatment suppresses rhinovirus-induced airw
286  airway hyperresponsiveness after 6 weeks of fluticasone treatment.
287  specific microbiota members were seen after fluticasone treatment.
288  in random order for 16 weeks: 250 microg of fluticasone twice daily (ICS step-up), 100 microg of flu
289 (n=374), 50 microg salmeterol and 500 microg fluticasone twice daily (n=358), or placebo (n=361) for
290 g salmeterol twice daily (n=372), 500 microg fluticasone twice daily (n=374), 50 microg salmeterol an
291 twice daily (LABA step-up), or 100 microg of fluticasone twice daily plus 5 or 10 mg of a leukotriene
292 trolled asthma while receiving 100 microg of fluticasone twice daily, to receive each of three blinde
293 95% confidence interval) of 0.59 (0.23-1.48) fluticasone versus placebo.
294 fidence interval) of 1.07 (0.68 to 1.70) for fluticasone versus placebo.
295 significantly lower in children treated with fluticasone versus those treated with placebo (mean diff
296  salmeterol in a fixed-dose combination with fluticasone was associated with the risk of a serious as
297 ebo); the difference between montelukast and fluticasone was not significant (P = .14).
298 dian value) tended to show more benefit with fluticasone, whereas those with a smoking history of >11
299                We compared mice treated with fluticasone with controls at various timepoints after in
300 stent asthma were assigned to receive either fluticasone with salmeterol or fluticasone alone for 26

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。
 
Page Top